Improvements likely due to underlying genomic instability, increased sensitivity to DNA-damaging chemotherapy.
Although the combination was deemed active in HR-positive, HER2-negative disease, findings don’t support further research.
Combining neoadjuvant pembrolizumab with radiotherapy prior to standard of care chemotherapy may increase pathologic complete responses rates in TNBC.
The oncolytic virus pelareorep may mediate priming of an adaptive immune response in women with early breast cancer.
The majority of responses seen were ongoing at data cutoff.
Women with lung, liver metastases and high PD-L1 expression saw a survival benefit.